Sonoma Pharmaceuticals, Inc.
SNOA
$3.24
-$0.03-0.92%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 39.58% | 6.95% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 39.58% | 6.95% | |||
| Cost of Revenue | 36.57% | 14.60% | |||
| Gross Profit | 44.81% | -4.19% | |||
| SG&A Expenses | -4.22% | 10.83% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 16.26% | 15.87% | |||
| Operating Income | 69.22% | -66.92% | |||
| Income Before Tax | 41.14% | -135.23% | |||
| Income Tax Expenses | -19,600.00% | -100.40% | |||
| Earnings from Continuing Operations | 56.97% | -59.92% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 56.97% | -59.92% | |||
| EBIT | 69.22% | -66.92% | |||
| EBITDA | 71.58% | -69.44% | |||
| EPS Basic | 57.10% | -57.18% | |||
| Normalized Basic EPS | 41.31% | -131.18% | |||
| EPS Diluted | 57.10% | -57.18% | |||
| Normalized Diluted EPS | 41.31% | -131.18% | |||
| Average Basic Shares Outstanding | 0.30% | 1.74% | |||
| Average Diluted Shares Outstanding | 0.30% | 1.74% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||